Migraine
Conditions
Brief summary
The difference in the incidence of migraine-like attacks during the entire observational period (until 12 hours post-administration) between cilostazol- and placebo-treated men with migraine without aura, The difference in the incidence of migraine-like attacks during the entire observational period (until 12 hours post-administration) between cilostazol-treated men and women with migraine without aura
Detailed description
The difference in the incidence of headache during the entire observational period (until 12 hours post-administration) between cilostazol- and placebo-treated men with migraine without aura, Difference in heart rate and mean arterial pressure until 90 minutes post-administration between cilostazol- and placebo-treated men with migraine without aura, Difference in the incidence of adverse events during the entire observational period (until 12 hours post-administration) between cilostazol- and placebo-treated men with migraine without aura
Interventions
DRUGround
DRUGCilostazol AL 100 mg Tabletten
DRUGWhite
DRUGconvex tablets with a diameter of 8 mm containing no active pharmaceutical ingredient. The composition (per 1000 tablets) includes lactose monohydrate (85 g)
DRUGpotato starch (86 g)
DRUGgelatin A (3 g)
DRUGpurified water (72 g) and magnesium stearate (0.9 g)
DRUGtalc (8.1 g).
DRUGfilmomhulde tabletten
Sponsors
Syddansk Universitet (University of Southern Denmark)
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The difference in the incidence of migraine-like attacks during the entire observational period (until 12 hours post-administration) between cilostazol- and placebo-treated men with migraine without aura, The difference in the incidence of migraine-like attacks during the entire observational period (until 12 hours post-administration) between cilostazol-treated men and women with migraine without aura | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference in the incidence of headache during the entire observational period (until 12 hours post-administration) between cilostazol- and placebo-treated men with migraine without aura, Difference in heart rate and mean arterial pressure until 90 minutes post-administration between cilostazol- and placebo-treated men with migraine without aura, Difference in the incidence of adverse events during the entire observational period (until 12 hours post-administration) between cilostazol- and placebo-treated men with migraine without aura | — |
Countries
Denmark
Outcome results
None listed